Skip to Content
  • Rank39
  • Previous Rank41
  • CEO
    Alex Gorsky
  • Address
    1 Johnson & Johnson Plaza, New Brunswick, NJ 08933
  • Website
    www.jnj.com

At 70 years old, Johnson & Johnson isn’t slowing down. The company, maker of Tylenol, Neutrogena, and other household brands, reported $13.8 billion in 2013 profits, a gain of more than 27% year-over-year. The pharmaceutical business had an exceptional year with 12% annual operational growth, making J&J the fastest growing top 10 pharmaceutical company in the U.S., Europe and Japan. CEO Alex Gorsky plans to sustain that growth through continued investment in research and development. Last year alone, the company allocated over $8 billion, or 11% of sales, to support R&D. Recent research efforts are paying off: About 25% of sales came from products J&J brought to market in the past five years.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Key Financials

$ Millions% change
Revenues71,3126.1
Profits
13831
27.4
Total Assets132,683-
Total Shareholder Equity74,053-
Market Value (on March 31, 2014)277,883-

Profit as a % of

Sales19.4
Assets10.4
Stockholders' Equity18.7

Earnings Per Share

Earnings Per Share ($)4.81
EPS % Change (from 2012)24.6
EPS % Change (5 year)1
EPS % Change (10 year)7.2

Total Return to Investors

Total Return to Investors34.6
Total Return to Investors (5 year, annualized)12.6
Total Return to Investors (10 year, annualized)
9